Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2016
[The efficacy of benzodiazepines and low-potent antipsychotics as adjunctive therapy of somatoform disorders].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pribytkov A A
Аннотация
OBJECTIVE: To assess the efficacy of monotherapy with sertraline or its combinations with phenazepam or thioridazine in patients with somatoform disorders.
MATERIAL AND METHODS: The open study included 65 patients divided into three groups according to the drug used. Clinical condition of the patients was evaluated with CGI and Hamilton scale. The Screening for Somatoform Symptoms 7 was administered as well.
RESULTS AND CONCLUSION: During the treatment, a significant decrease in the severity of somatoform disorders was observed in all groups. The more rapid development of therapeutic effect, including the reduction in anxiety symptoms in the sertraline + phenazepam group, was found. There were no significant differences between the sertraline group and the sertraline+ thioridazine group. The differences were identified only during three weeks of treatment while there were no between-group differences in the 4th week. In accordance to these results, the duration of adjunctive therapy with benzodiazepines should be limited in time.
MATERIAL AND METHODS: The open study included 65 patients divided into three groups according to the drug used. Clinical condition of the patients was evaluated with CGI and Hamilton scale. The Screening for Somatoform Symptoms 7 was administered as well.
RESULTS AND CONCLUSION: During the treatment, a significant decrease in the severity of somatoform disorders was observed in all groups. The more rapid development of therapeutic effect, including the reduction in anxiety symptoms in the sertraline + phenazepam group, was found. There were no significant differences between the sertraline group and the sertraline+ thioridazine group. The differences were identified only during three weeks of treatment while there were no between-group differences in the 4th week. In accordance to these results, the duration of adjunctive therapy with benzodiazepines should be limited in time.